stockrow
Saturday 7 November 2026
Export OABI’s income statement to Excel — free account
OmniAb, Inc.
OABI Healthcare Biotechnology
OmniAb, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.7 million, down 29.3% from fiscal 2024.
- Revenue
- +78.3%
- EPS
- +14.3%
- Free cash flow
- +206.3%
Quarter to September 2026, against a year earlier
5.02
0.19
+3.93%
Follow OABI
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
11.26 | 6.96 | 8.24 | 15.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 269.46 | |
P/Operating CF |
(37.05) | (40.97) | 118.27 | 60.64 | |
P/B ratio |
0.79 | 0.77 | 1.22 | 2.57 | |
Price to Tangible BV |
3.63 | 3.38 | 5.26 | 12.29 | |
EV/Sales |
8.37 | 5.26 | 6.89 | 14.35 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.28) | (5.97) | (14.99) | 216.46 | |
EV/FCF |
(4.59) | (6.61) | (14.60) | 242.48 | |
Quick Ratio |
3.78 | 4.55 | 4.53 | 3.96 | |
Current Ratio |
4.02 | 4.80 | 4.80 | 4.21 | |
Net Debt/EBITDA |
6.51 | 60.29 | 20.28 | 5.20 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.06 | 0.10 | 0.13 | 0.13 | |
Operating CF/Net income |
0.40 | 0.64 | (0.46) | (0.67) | |
Capex/Depreciation |
0.00 | (0.02) | (0.03) | 0.00 | |
Research and Development Expense of Revenue |
166.06% | 66.82% | 71.46% | 239.24% | |
Selling, General and Administrative Expense of Revenue |
81.65% | 45.88% | 49.59% | 181.42% | |
Intangible Assets out of Total Assets |
0.70 | 0.69 | 0.69 | 0.68 | |
Share Based Compensation of Revenue |
43.05% | 23.15% | 23.55% | 76.58% | |
Graham Net Nets |
0.15 | 0.17 | 0.11 | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(30.81%) | (29.30%) | (14.63%) | (6.85%) | |
Free Cash Flow Yield |
(16.18%) | (11.43%) | (5.73%) | 0.37% | |
Revenue per Share |
0.07 | 0.11 | 0.10 | 0.03 | |
Operating CF per Share |
(0.05) | (0.04) | 0.02 | 0.08 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.04) | 0.02 | 0.08 | |
Cash per Share |
0.48 | 0.38 | 0.40 | 0.50 | |
Shareholders Equity per Share |
2.35 | 2.05 | 2.02 | 1.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.35 | 2.05 | 2.02 | 1.93 | |
Free Cash Flow |
(5.68) | (5.08) | 2.57 | 10.58 | |
Working Capital |
49.09 | 51.56 | 52.26 | 54.13 | |
Capital Expenditures |
(0.01) | (0.17) | (0.11) | 0.00 | |
Net Current Asset Value |
31.45 | 34.12 | 36.03 | 29.22 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.33 | 9.56 | 6.52 | 2.83 | |
Average Payables |
2.09 | 1.79 | 2.03 | 1.66 | |
Average Assets |
313.24 | 299.92 | 292.97 | 300.31 | |
Average Common Equity |
277.32 | 268.08 | 261.17 | 263.30 |
Columns are period end dates · fundamentals updated 6 Nov 2026